柳氮磺胺吡啶联合培菲康治疗溃疡性结肠炎的临床研究

目的探讨柳氮磺胺吡啶联合培菲康治疗溃疡性结肠炎患者的临床疗效。方法将52例溃疡性结肠炎患者随机分成两组。治疗组采用柳氮磺胺吡啶联合培菲康治疗（n=27）;对照组单纯采用柳氮磺胺吡啶治疗（n=25）,观察两组患者治疗后临床活动指数及临床综合疗效。结果两组治疗前临床活动指数：治疗组为7.85±2.93,对照组为7.68±2.88,两组差别无统计学意义（P〉0.05）,治疗后临床活动指数治疗组为1.56±1.78,对照组为3.64±2.50,两组均较治疗前下降了（P〈0.001）,但治疗组临床活动指数的改善优于对照组（P〈0.05）;治疗后两组临床综合疗效比较,治疗组完全缓解20例,有效5例,无效2例,总有效率92.6%,对照组完全缓解11名,有效6例,无效8例,总有效率68%,治疗组临床综合疗效也优于与对照组,两组完全缓解率和总有效率有显著差别（P〈0.05）。结论柳氮磺胺吡啶联合培菲康治疗溃疡性结肠炎患者有利于临床症状的好转,提高临床疗效。     

阴式子宫瘢痕妊娠病灶清除术的临床疗效评价

目的 观察阴式子宫瘢痕妊娠病灶清除术治疗剖宫产术后瘢痕妊娠的意义.方法 选取我院2018年10月—2019年10月收治的64例剖宫产术后瘢痕妊娠患者的临床资料,根据手术方案的不同,将实施阴式子宫瘢痕妊娠病灶清除术的病例作为观察组(n=33),将选择腹腔镜子宫瘢痕妊娠病灶消除术的病例作为对照组(n=31).比较两组手术疗...     

Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021

BackgroundTo assess the temporal changes in the characteristics of ischemic stroke drug clinical trials conducted in mainland China in 2005–2021.MethodsA statistical analysis of registered clinical trials on ischemic stroke was performed using the platform of the Center for Drug Evaluation of China National Medical Products Administration, the Chinese Clinical Trial Registry, and ClinicalTrials.gov websites.ResultsFrom January 1, 2005 to August 1, 2021, a total of 384 registered drug clinical trials on ischemic stroke were identified in mainland China. Over time, the number of trials gradually increased each year, with a significant growth in 2014, from 16 in 2013 to 42 in 2014. Phase IV trials (31.8%) accounted for the majority, followed by phase II (16.4%), phase I (10.9%), and phase III (8.6%). In terms of sponsorship, the proportion of investigator‐initiated trials (IITs) (60.7%) was higher than industry‐sponsored trials (ISTs) (39.3%). Additionally, trials involving traditional Chinese medicines (TCMs) (36.2%) accounted for the largest proportion, followed by trials involving antithrombotic therapy (19.5%) and cerebral protection agents (16.7%). Furthermore, over the past 17 years, the number of leading drug clinical trial units for ischemic stroke in mainland China has continuously increased. The leading principal units from Beijing, Shanghai, Guangdong, Jiangsu, and Liaoning accounted for the majority of the trials (67.4%).ConclusionIn the past 17 years, great progress has been made in the research and development (R&D) of drugs and clinical trials for ischemic stroke in mainland China. The most extensive progress was observed in TCMs, antithrombotic therapy, and cerebral protection agents. More clinical trials are needed to confirm whether the newly developed drugs can improve the clinical efficacy of ischemic stroke. Simultaneously, more pharmaceutical R&D efforts of innovative drugs are warranted.     

Effectiveness and safety of Korean medicine treatment based on the clinical practice guidelines in patients with acute peripheral facial palsy: A protocol for a multicenter,prospective, observational study

Introduction:Peripheral facial palsy (PFP) results in weakness or paralysis of the affected side of the face. In Korea, there is a high demand for Korean medicine treatment for PFP. The clinical practice guidelines (CPGs) of Korean medicine for facial palsy were developed; however, there remains insufficient evidence to support the effectiveness and safety of Korean medicine treatment. Thus, this study aimed to evaluate the effectiveness and safety of Korean medicine treatment based on the CPGs in patients with acute PFP.Methods:This is a multicenter, prospective, observational study. The participants will be recruited from one Korean medicine hospital and eight Korean medicine clinics. The participants will receive Korean medicine treatments based on the CPGs, fill in survey questionnaires, and undergo electrophysiologic testing. The changes in House-Brackmann (H-B) grade, movement of the lip and eye, symptoms related to or accompanied by facial palsy, Facial Disability Index, EuroQol 5-dimension 5-level (EQ-5D-5L), and EuroQol Visual Analogue Scale (EQ-VAS), and the results of electromyography (EMG), electroneurography (ENoG), and Blink Reflex test will be analyzed. For the safety analysis, adverse events will be recorded, and for the feasibility analysis, the results of the Was It Worth It questionnaire will be assessed.Conclusion:We expect to draw real-world clinical data on the effectiveness and safety of Korean medicine treatment based on the CPGs in patients with acute PFP from this study. It would be the basis for complementing and improving the CPGs and provide the basis of clinical and policy decision-making.Trial registration:This study was approved by the Institutional Review Board of Kyung Hee University Korean Medicine Hospital (2021-06-005-001), and registered with the Korean Clinical Trial Registry (CRIS), Republic of Korea (KCT0006562).     

医案3则话辨证

通过对巅顶头痛、大便秘结和肌肤肿胀等3则医案治疗经过的总结,阐述中医辨证论治在临床中的重要性。     

胡建华治疗多发性抽动-秽语综合征经验举隅

全国名老中医胡建华老师治疗多发性抽动-秽语综合征经验丰富。胡老认为肝风扰动,痰阻窍络,心神不宁为该病病机;平肝熄风,助以化痰定志、养心安神为治疗原则,加味四虫汤为临证基本方。     

针刺治疗假性球麻痹吞咽困难89例

假性球麻痹属于上运动神经元延髓麻痹,常见于两侧半球血管病变,如脑梗死、多发性腔隙性梗塞、脑出血等疾病。临床表现为构音障碍,吞咽困难,饮水呛咳,患者不能进食、进水,出现营养不良。笔者运用针刺治疗假性球麻痹89例,疗效显著,现报道如下。     

五步复位法治疗腰椎间盘突出症临床观察

[目的]观察五步复位法治疗腰椎间盘突出症的临床疗效.[方法]将2018年4月至2019年6月于浙江中医药大学附属第三医院住院的符合标准的124例腰椎间盘突出症患者按随机数字表法分为两组,五步复位法组63例采用五步复位法治疗,传统推拿法组61例采用传统推拿法治疗,两组患者均隔日治疗1次,每周3次,1周为1个疗程.治疗2个...     

电针防治多发性腺瘤性结肠息肉再发的临床观察

目曲：观察电针治疗对多发性腺瘤性结肠息肉内镜治疗后再发率的影响。方法：90例患者随机分为两组。治疗组50例采用电针治疗3个疗程;对照组不做任何治疗。观察两组3年后再发率和腹痛、大便症状改善情况。结幂：治疗组和对照组的再发率分别为8．0％和32．5％,有明显差异（P〈0．01）;治疗组腹痛及大便失常等的改善也优于对照组（P〈0．01）。结论：电针可有效控制经内镜治疗后多发性腺瘤性结肠息肉的再发。